MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3...

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001...

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...